Genetic Engineering News Reports on Neurobiotechnology Developments

Genetic Engineering News Reports on Neurobiotechnology Developments: "Biotechnology and pharmaceutical companies view the brain as the number-one target for drug development over the next decade, reports Genetic Engineering News (GEN; www.genengnews.com). Numerous public and private companies are developing novel therapeutics for Alzheimer's disease, Parkinson's disease, stroke, epilepsy, pain, depression, anxiety, schizophrenia, obesity, hearing loss, and sleep disorders, according to the July issue of GEN."

The press release notes that Targacept is targeting specific NNR subtypes, and Saegis is developing drugs including SGS742 for cognition-enhancement.